Aldeyra Therapeutics, Inc.

( )
ALDX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 2.91%69.000.0%$1792.09m
GILDGilead Sciences, Inc. -0.22%73.341.0%$1310.05m
AMGNAmgen, Inc. 0.73%226.431.3%$654.36m
REGNRegeneron Pharmaceuticals, Inc. 1.59%569.912.5%$571.28m
NVAXNovavax, Inc. -7.91%46.11102.0%$561.17m
VRTXVertex Pharmaceuticals, Inc. 0.12%284.961.9%$530.07m
BIIBBiogen, Inc. 0.02%304.531.6%$421.31m
ILMNIllumina, Inc. 1.51%354.703.5%$346.79m
SRNESorrento Therapeutics, Inc. 0.80%5.071.8%$295.47m
SGENSeattle Genetics, Inc. 1.02%155.776.1%$235.46m
ALXNAlexion Pharmaceuticals, Inc. 0.36%101.502.0%$221.68m
MGNXMacroGenics, Inc. 0.84%25.376.2%$199.40m
CODXCo-Diagnostics, Inc. 2.94%18.550.0%$198.21m
AAgilent Technologies, Inc. 5.24%84.981.6%$189.94m
BMRNBioMarin Pharmaceutical, Inc. 2.80%97.514.3%$148.95m

Company Profile

Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.